Plain-English translation of NCT06311708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that watches how a genetic heart condition called ARVC (arrhythmogenic right ventricular cardiomyopathy) develops over time in patients. The study is particularly interested in whether patients have natural immunity to a type of virus vector that might be used in future gene therapy treatments. You would continue your normal care while researchers collect blood samples and health information to better understand your condition.
Researchers are developing new gene therapy treatments for ARVC, but they need to understand how many patients already have immunity to the treatment method they want to use. This study will help them know who might benefit from this new treatment in the future and identify any safety considerations.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your regular heart care from your doctor while enrolled in this study. Once a year, you'll have blood drawn to measure heart-related markers and will complete questionnaires about your quality of life and heart health. The study lasts up to 5 years, and you may also have genetic testing done if you consent. You won't receive any experimental medication—this is purely an observation and data collection study.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States